Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis, spinal muscular atrophy (SMA) type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing novel medicines for patients living with rare diseases including Lambert-Eaton myasthenic syndrome, congenital myasthenic syndromes, MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and infantile spasms. The company was founded by Huckel E. Hubert and Patrick J. McEnany in January 2002 and is headquartered in Coral Gables, FL.

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?

Catalyst (CPRX) Up 13.3% Since Last Earnings Report: Can It Continue?

Pharmaceuticals stock is trading above a 3-week base on heavy volume. The company is first in its industry.

Pharmaceuticals Stock Clears A Base Following Two Prior Gap-Ups

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

Catalyst Pharmaceutical (CPRX) Just Reclaimed the 20-Day Moving Average

Veru

Their recent successes with commercializing medicines are paying off.

Got $1,500? Buy These 2 Surging Growth Stocks

Catalyst Pharmaceuticals is now looking for its second act after launching a LEMS treatment. Could CPRX stock investors see a buyout?

Catalyst Pharmaceuticals' CEO Wants In On The Biotech Buying Spree

Catalyst (CPRX) could produce exceptional returns because of its solid growth attributes.

3 Reasons Why Catalyst (CPRX) Is a Great Growth Stock

Does Catalyst Pharmaceutical (CPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Catalyst Pharmaceutical (CPRX) is a Great Momentum Stock to Buy

CORAL GABLES, Fla., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at the upcoming Citi's 17th Annual BioPharma Conference.

Catalyst Pharmaceuticals To Participate in Citi's 17th Annual BioPharma Conference

It might not last forever, but for now they're preparing to grow aggressively.

Got $2,500? These 2 Small-Cap Monsters Are Crushing Tesla Stock

Catalyst (CPRX) beat earnings and sales estimate in second-quarter 2022 earnings. Consequently, the stock surges.

Catalyst Pharmaceuticals (CPRX) Q2 Earnings Top, Revenues Up

Start Time: 08:30 January 1, 0000 9:12 AM ET Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2022 Earnings Conference Call August 10, 2022, 08:30 AM ET Company Participants Patrick McEnany - Co-Founder, Chairman, President and CEO Jeff Del Carmen - Chief Commercial Officer Steven Miller - COO and Chief Scientific Officer Ali Grande - VP, CFO and Treasurer Conference Call Participants Charles Duncan - Cantor Fitzgerald Joe Catanzaro - Piper Sandler Les Sulewski - Truist Securities Operator Greetings, and welcome to the Catalyst Pharmaceuticals Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q2 2022 Results - Earnings Call Transcript

Catalyst (CPRX) delivered earnings and revenue surprises of 17.65% and 7.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Top Estimates

Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53.0 Million, a 57.7% YoY Increase

Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update

The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ET

Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022

Catalyst's (CPRX) price rallies on the back of the robust performance of its lead drug, Firdapse, approved for treating LEMS in adults. The company is also trying to launch Firdapse in the international markets.

Catalyst Pharmaceuticals (CPRX) Rallies 43% YTD: Here's Why

Catalyst (CPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Catalyst (CPRX) Stock Jumps 10%: Will It Continue to Soar?

Catalyst (CPRX) settles patent litigation disputes related to Firdapse, its LEMS drug. This settlement further strengthens CPRX's intellectual property hold over the drug through 2034.

Catalyst (CPRX) Settles Patent Dispute Over Sole Marketed Drug

As Part of the Settlement, Catalyst has Acquired Certain of Jacobus' Intellectual Property Rights, Including the U.S. and Mexico Rights to Ruzurgi® As Part of the Settlement, Catalyst has Acquired Certain of Jacobus' Intellectual Property Rights, Including the U.S. and Mexico Rights to Ruzurgi®

Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical

Catalyst (CPRX) Up 6.9% Since Last Earnings Report: Can It Continue?

Having a small drug development pipeline is a big risk, but it also leaves the door open potentially for big gains.

Is Now the Time to Buy This Risky Stock With Huge Upside Potential?

CORAL GABLES, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Chairman and CEO of Catalyst, along with other members of the management team, will participate at two upcoming conferences. The management team will also host one-on-one investor meetings at the conferences.

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.

Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2022 Earnings Conference Call May 11, 2022 8:30 AM ET Company Participants Ali Grande - Vice President, Chief Financial Officer and Treasurer Patrick McEnany - Chairman and Chief Executive Officer Jeff Del Carmen - Chief Commercial Officer Steven Miller - Chief Operating Officer and Chief Scientific Officer Conference Call Participants Joe Catanzaro - Piper Sandler Charles Duncan - Cantor Fitzgerald Les Sulewski - Truist Securities Scott Henry - ROTH Capital Operator Greeting and welcome to the Catalyst Pharmaceuticals CPRX First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.

Catalyst Pharmaceuticals, Inc. (CPRX) CEO Patrick McEnany on Q1 2022 Results - Earnings Call Transcript

Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates

Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY

News for Catalyst Pharmaceuticals Stock (CPRX)